The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Variation in FOLFOX, FOLFIRI, and FOLFOXIRI effects on CD8+ T cell and PDL1 levels in MSS CRC patients.
 
Lindsey Carlsen
No Relationships to Disclose
 
Andrew Elliott
Employment - Caris Life Sciences
 
Marzia Capelletti
No Relationships to Disclose
 
Emil Lou
Honoraria - Boston Scientific; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure
Research Funding - Intima; Novocure
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan
 
John Marshall
Employment - Caris Life Sciences; Indivumed
Leadership - 2curex
Honoraria - AstraZeneca/MedImmune; Bayer/Onyx; Caris Life Sciences; Daiichi Sankyo/Lilly; Merck; Pfizer; Seagan; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Genentech/Roche; Merck; Pfizer; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Caris Life Sciences; Merck; Pfizer; Seagan; Taiho Pharmaceutical
Research Funding - Genentech; Natera
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; GlaxoSmithKline; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - Bayer; BMS; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Philip A. Philip
No Relationships to Disclose
 
Michael J. Hall
Consulting or Advisory Role - Eisai; Natera
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - I share a patent with several Fox Chase investigators for a novel method to investigate hereditary CRC genes (Inst)
Travel, Accommodations, Expenses - GRAIL
Other Relationship - Caris Life Sciences; Invitae; Myriad Genetics
 
George W. Sledge
Leadership - Syndax; Tessa Therapeutics
Stock and Other Ownership Interests - Pionyr; Syndax; Tessa Therapeutics
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; G1 Therapeutics; GRAIL; Synaffix; Syndax; Verseau Therapeutics
Research Funding - Genentech/Roche (Inst); Pfizer (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Tessa Therapeutics; Verseau Therapeutics
 
Alexander G Raufi
No Relationships to Disclose
 
Rimini Breakstone
No Relationships to Disclose
 
Khaldoun Almhanna
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - AstraZeneca; Eisai
 
Benedito A. Carneiro
Consulting or Advisory Role - Eisai; Seagen; Tempus
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Dragonfly Therapeutics (Inst); MiNK Therapeutics (Inst); Pfizer (Inst); Repare Therapeutics (Inst)
 
Howard Safran
No Relationships to Disclose
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Chimerix; Oncoceutics; p53-Therapeutics; SMURF-Therapeutics
Consulting or Advisory Role - Rain Therapeutics
Research Funding - Chimerix; D&D Pharmatech
Patents, Royalties, Other Intellectual Property - Patent on therapeutic targeting on hypoxia-inducible factors; Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
(OPTIONAL) Uncompensated Relationships - As above